Heparin sodium

肝素钠

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameHeparin sodium
Drug Alias Nameheparina de sodioheparinum natricumTraumalitanLiqueminHepalean +[10] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionAntithrombin-III activators
TargetsAntithrombin-III
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaArterial Thromboembolism +[29] 
Global Approved IndicationsDisseminated Intravascular CoagulationBlood Coagulation DisordersVenous Thromboembolism +[6] 
Approved Indications in ChinaDisseminated Intravascular CoagulationBlood Coagulation DisordersEmbolism and Thrombosis
Original Approved Country/TerritoryUnited States
Original Approved Date1939/02/09
Country/TerritoryCanadaUnited StatesPakistan +[15] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesTabba Heart InstituteUniversity Of ManitobaKent Pharmaceuticals Ltd +[12] 
Inactive CompaniesUtah State UniversityRegado Biosciences IncAzidus Brasil +[8] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Community Acquired PneumoniaArterial Thromboembolism +[14] 
Inactive IndicationsShockThrombocytopeniaThrombosis +[15] 

Other Information

ATC CodeB01AB01C05BA03S01XA14
Related LinksWikipediaDrugBankKEGG